Product Description
Mechanisms of Action: XO Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: India | Japan
Approved Indications: None
Known Adverse Events: None
Company: Sanwa Kagaku Kenkyusho Co., Ltd.
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 3
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Gout
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
CTR20253654 |
CTR20253654 | P1 |
Completed |
Gout |
2025-12-06 |
2025-12-21 |
Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20253655 |
CTR20253655 | P1 |
Completed |
Gout |
2025-11-30 |
2025-12-14 |
Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20242693 |
CTR20242693 | P2 |
Completed |
Unknown |
2025-03-26 |
2026-03-08 |
Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |